The IPKat

Benefits and pitfalls of functional patent claims (and why the UK is out of step with the EPO on claim construction): Astellas v Teva [2023] EWHC 2571 (Pat)

FibroGen v. Akebia: Arnold LJ addresses insufficiency, equivalence, second medical use claims, and much more

A case for our times: Ambiguity, insufficiency and uncertainty (Anan Kasei v Neo [2019] EWCA Civ 1646)

Court of Appeal, following EPO, reverses Carr J in Regeneron v Kymab dispute

Canadian Supreme Court holds promise doctrine "unsound" in AstraZeneca v Apotex Nexium dispute

Gilead triumphant as Court of Appeal upholds Arnold J in Idenix's Sovaldi appeal

Biogen, Lundbeck, Lord Hoffmann and a tour de force

More than the patentee deserves? No problem ...